American Regent Animal Health announced it will begin selling Adequan® i.m. (polysulfated glycosaminoglycan) through veterinary distribution in December 2020. As of December 2, 2020, the company has finalized agreements with several national distributors. It is also working to expand this network to distribute the product and provide veterinarians with increased product support, streamlined ordering, and better access to resources that educate horse owners about the effects of equine degenerative joint disease (DJD).
“Listening to our customers and finding new opportunities to meet their needs is our top priority,” said Joel Steckler, vice president and general manager, Animal Health at American Regent. “In this spirit, we are pleased to make Adequan i.m. available via veterinary distribution.”
Veterinarians will be able to purchase Adequan i.m. from the distributor of their choice while receiving continued support from dedicated American Regent Animal Health sales professionals and the company’s Technical Services Veterinarians. American Regent Animal Health has achieved success with a similar approach to distributing Adequan Canine (polysulfated glycosaminoglycan), in which veterinarians report they appreciate the increased touchpoints and diversity of purchasing options.
To better support this distribution channel, American Regent Animal Health will redesign its equine sales team model in the coming weeks. Coupled with the company’s distribution partners, the revamped structure will enable American Regent Animal Health to increase its already strong industry involvement.
“Engaging with the equine community is one of the central tenets of what we do,” Steckler said. “Combined with our ongoing investment in and commitment to research and development, our team looks forward to continued connections and reaching more veterinarians across the country so they’re able to support more horses with DJD.”
Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Important Safety Information
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For more information and Full Prescribing Information, visit www.adequan.com.
About American Regent Animal Health
American Regent Animal Health, a division of American Regent, Inc., is committed to advancing animal health with proven FDA-approved products like Adequan® (polysulfated glycosaminoglycan). The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163.